{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T09:02:57Z","timestamp":1791277377135,"version":"4.1.0"},"update-to":[{"DOI":"10.1002\/14651858.cd000402.pub4","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:00:00Z","timestamp":1761177600000}}],"reference-count":169,"publisher":"Wiley","issue":"10","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd000402.pub5","type":"journal-article","created":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T11:32:03Z","timestamp":1761219123000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Hormone therapy in postmenopausal women and risk of endometrial hyperplasia or endometrial cancer"],"prefix":"10.1002","volume":"2025","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-5646-782X","authenticated-orcid":false,"given":"Dongah","family":"Kim","sequence":"additional","affiliation":[{"name":"IVF Australia; Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Jordan","sequence":"additional","affiliation":[{"name":"Faculty of Medical and Health Sciences; University of Auckland; Auckland New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Casciola","sequence":"additional","affiliation":[{"name":"Department of Obstetrics, Gynaecology and Reproductive Sciences, FMHS; The University of Auckland; Auckland New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mackenzie","family":"Ferguson","sequence":"additional","affiliation":[{"name":"Department of Obstetrics, Gynaecology and Reproductive Sciences, FMHS; The University of Auckland; Auckland New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimee","family":"Humphries","sequence":"additional","affiliation":[{"name":"Department of Obstetrics, Gynaecology and Reproductive Sciences, FMHS; The University of Auckland; Auckland New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Bofill Rodriguez","sequence":"additional","affiliation":[{"name":"Department of Obstetrics, Gynaecology and Reproductive Sciences; FMHS, The University of Auckland; Auckland New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle R","family":"Wise","sequence":"additional","affiliation":[{"name":"Department of Obstetrics, Gynaecology and Reproductive Sciences, FMHS; The University of Auckland; Auckland New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,10,23]]},"reference":[{"issue":"153","key":"10.1002\/14651858.CD000402.pub5-BIB0001|cit1","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1093\/aje\/153.9.865","article-title":"Factors associated with age at natural menopause in a multiethnic sample of midlife women","volume":"1","author":"Gold","year":"2001","journal-title":"American Journal of Epidemiology"},{"issue":"23","key":"10.1002\/14651858.CD000402.pub5-BIB0002|cit2","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1080\/13697137.2020.1739642","article-title":"Clinical management of vaginal bleeding in postmenopausal women","volume":"4","author":"Carugno","year":"2020","journal-title":"Climacteric"},{"key":"10.1002\/14651858.CD000402.pub5-BIB0003|cit3","unstructured":"National Institute for Health and Care Excellence (NICE) Menopause: identification and management Available at https:\/\/www.nice.org.uk\/guidance\/ng23"},{"key":"10.1002\/14651858.CD000402.pub5-BIB0004|cit4","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1177\/2053369120983154","article-title":"BMS, IMS, EMAS, RCOG and AMS joint statement on menopausal hormone therapy and breast cancer risk in response to EMA Pharmacovigilance Risk Assessment Committee recommendations in May 2020","volume":"27","author":"Hamoda","year":"2021","journal-title":"Post Reproductive Health"},{"issue":"101815","key":"10.1002\/14651858.CD000402.pub5-BIB0005|cit5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.beem.2023.101815","article-title":"Progestogens for endometrial protection in combined menopausal hormone therapy: A systematic review","volume":"22","author":"Stute","journal-title":"Best Practice & Research Clinical Endocrinology & Metabolism"},{"issue":"5","key":"10.1002\/14651858.CD000402.pub5-BIB0006|cit6","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004861.pub2","article-title":"Types of progestogens in combined oral contraception: effectiveness and side-effects","author":"Lawrie","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD000402.pub5-BIB0007|cit7","unstructured":"Mirkov S Equivalent progestogen doses for menopausal hormone replacement therapy - a pragmatic approach (as supplied 2021) Data on File"},{"key":"10.1002\/14651858.CD000402.pub5-BIB0008|cit8","unstructured":"Australasian Menopause Society AMS Guide to Equivalent MHT\/HRT Doses Available at www.menopause.org.au"},{"key":"10.1002\/14651858.CD000402.pub5-BIB0009|cit9","doi-asserted-by":"publisher","first-page":"564781","DOI":"10.3389\/fendo.2021.564781","article-title":"Risks, benefits, and treatment modalities of menopausal hormone therapy: current concepts","volume":"12","author":"Mehta","year":"2021","journal-title":"Frontiers in Endocrinology"},{"issue":"7","key":"10.1002\/14651858.CD000402.pub5-BIB0010|cit10","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1097\/GME.0000000000000921","article-title":"The 2022 hormone therapy position statement of the North American Menopause Society","volume":"29","author":"The NAMS 2022 Hormone Therapy Position Statement Advisory Panel","year":"2022","journal-title":"Menopause"},{"issue":"8","key":"10.1002\/14651858.CD000402.pub5-BIB0011|cit11","doi-asserted-by":"publisher","first-page":"2354","DOI":"10.1210\/jcem.80.8.7629229","article-title":"Core body temperature and circadian rhythm of hot flashes in menopausal women","volume":"80","author":"Freedman","year":"1995","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"2","key":"10.1002\/14651858.CD000402.pub5-BIB0012|cit12","doi-asserted-by":"publisher","first-page":"109","DOI":"10.3109\/13697137.2015.1129166","article-title":"2016 IMS Recommendations on women's midlife health and menopause hormone therapy","volume":"19","author":"Baber","journal-title":"Climacteric"},{"issue":"4","key":"10.1002\/14651858.CD000402.pub5-BIB0013|cit13","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1080\/13697137.2016.1196047","article-title":"Revised global consensus statement on menopausal hormone therapy","volume":"19","author":"Villiers","year":"2016","journal-title":"Climacteric"},{"issue":"9483","key":"10.1002\/14651858.CD000402.pub5-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/S0140-6736(05)66519-1","article-title":"Treatment of menopausal symptoms: what shall we do now?","volume":"366","author":"Hickey","year":"2005","journal-title":"Lancet"},{"issue":"7596","key":"10.1002\/14651858.CD000402.pub5-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1136\/bmj.39153.522535.BE","article-title":"Managing the menopause","volume":"334","author":"Roberts","year":"2007","journal-title":"British Medical Journal"},{"issue":"6","key":"10.1002\/14651858.CD000402.pub5-BIB0016|cit16","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/j.ajog.2009.02.032","article-title":"Incidence of endometrial hyperplasia","volume":"200","author":"Reed","year":"2009","journal-title":"American Journal of Obstetrics and Gynecology"},{"issue":"1","key":"10.1002\/14651858.CD000402.pub5-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM197901043000103","article-title":"Endometrial cancer and estrogen use. Report of a large case-control study","volume":"300","author":"Antunes","year":"1979","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD000402.pub5-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1056\/NEJM197709152971102","article-title":"Oestrogen and endometrial carcinoma: an independent pathology review supporting original size estimate","volume":"297","author":"Gardan","year":"1977","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD000402.pub5-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/0029-7844(94)00383-O","article-title":"Hormone replacement therapy and endometrial cancer risk: a meta-analysis","volume":"85","author":"Grady","year":"1995","journal-title":"Obstetrics and Gynecology"},{"key":"10.1002\/14651858.CD000402.pub5-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0015-0282(01)01828-3","article-title":"Endometrial effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate","volume":"76","author":"Pickar","year":"2001","journal-title":"Fertility and Sterility"},{"key":"10.1002\/14651858.CD000402.pub5-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1056\/NEJM197512042932302","article-title":"Association of exogenous oestrogen and endometrial carcinoma","volume":"293","author":"Smith","year":"1977","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD000402.pub5-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1056\/NEJM197512042932303","article-title":"Increased risk of endometrial carcinoma amongst users of conjugated oestrogens","volume":"293","author":"Ziel","year":"1975","journal-title":"New England Journal of Medicine"},{"issue":"8","key":"10.1002\/14651858.CD000402.pub5-BIB0023|cit23","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000402.pub4","article-title":"Hormone therapy in postmenopausal women and risk of endometrial hyperplasia","author":"Susan","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD000402.pub5-BIB0024|cit24","first-page":"373","article-title":"Norethindrone acetate and estradiol-induced endometrial hyperplasia","volume":"96","author":"Kurman","year":"2000","journal-title":"Obstetrics and Gynecology"},{"key":"10.1002\/14651858.CD000402.pub5-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/j.1447-0756.1997.tb00836.x","article-title":"The behaviour of endometrial hyperplasia: a prospective study","volume":"28","author":"Terakawa","year":"1997","journal-title":"Journal of Obstetrics and Gynaecology Research"},{"issue":"4","key":"10.1002\/14651858.CD000402.pub5-BIB0026|cit26","doi-asserted-by":"publisher","first-page":"e0232231","DOI":"10.1371\/journal.pone.0232231","article-title":"Concurrent and future risk of endometrial cancer in women with endometrial hyperplasia: A systematic review and meta-analysis","volume":"15","author":"Doherty","year":"2020","journal-title":"Public Library of Science One"},{"key":"10.1002\/14651858.CD000402.pub5-BIB0027|cit27","first-page":"279","article-title":"Effect of a unique constant estrogen, pulsed progestin hormone replacement therapy containing 17B estradiol and norgestimate on endometrial histology","volume":"44","author":"Corson","year":"1999","journal-title":"International Journal of Fertility"},{"key":"10.1002\/14651858.CD000402.pub5-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"345","DOI":"10.2165\/00002018-199005050-00004","article-title":"A risk benefit assessment of oestrogen therapy in post menopausal women","volume":"5","author":"Cust","year":"1990","journal-title":"Drug Safety"},{"key":"10.1002\/14651858.CD000402.pub5-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/0029-7844(95)00115-8","article-title":"Combined continuous hormone replacement therapy: a clinical review","volume":"86","author":"Udoff","year":"1995","journal-title":"Obstetrics and Gynecology"},{"key":"10.1002\/14651858.CD000402.pub5-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3109\/00016347709156348","article-title":"The effects of cyclical oestrogen therapy and sequential oestrogen therapy on the endometrium of postmenopausal women","volume":"65","author":"Whitehead","year":"1977","journal-title":"Acta Obstetrica et Gynecologica Scandinavica Supplement"},{"key":"10.1002\/14651858.CD000402.pub5-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1093\/oxfordjournals.bmb.a072553","article-title":"HRT: developments in therapy","volume":"48","author":"Ellerington","year":"1992","journal-title":"British Medical Bulletin"},{"key":"10.1002\/14651858.CD000402.pub5-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0020-7292(00)00342-8","article-title":"Constant estrogen, intermittent progestogen vs continuous combined hormone replacement: tolerability and effect on vasomotor symptoms","volume":"72","author":"Rozenberg","year":"2001","journal-title":"International Journal of Gynaecology and Obstetrics"},{"key":"10.1002\/14651858.CD000402.pub5-BIB0033|cit33","unstructured":"Lefebvre C Glanville J Briscoe S Littlewood A Marshall C Technical Supplement to Chapter 4: Searching for and selecting studies. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.4 (updated February 2024). Cochrane, 2024 Available at training.cochrane.org\/handbook\/archive\/v6.4"},{"key":"10.1002\/14651858.CD000402.pub5-BIB0034|cit34","unstructured":"Oransky I Marcus A Retraction Watch Database Version: 1.0.8.0 Available at https:\/\/retractiondatabase.org\/RetractionSearch.aspx"},{"key":"10.1002\/14651858.CD000402.pub5-BIB0035|cit35","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD000402.pub5-BIB0036|cit36","unstructured":"Higgins JP Altman DG Sterne JA Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017). Cochrane, 2017 Available at www.training.cochrane.org\/handbook\/archive\/v5.2"},{"key":"10.1002\/14651858.CD000402.pub5-BIB0037|cit37","unstructured":"Deeks JJ Higgins JP Altman DG Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.4 (updated August 2023), Cochrane, 2023 Available at www.training.cochrane.org\/handbook\/archive\/v6.4"},{"key":"10.1002\/14651858.CD000402.pub5-BIB0038|cit38","unstructured":"Review Manager (RevMan) The Cochrane Collaboration 2025"},{"key":"10.1002\/14651858.CD000402.pub5-BIB0039|cit39","first-page":"14","article-title":"Estrogens; conjugated and esterified therapeutic substitution","volume":"19","author":"Ansbacher","year":"1994","journal-title":"Female Patient"},{"key":"10.1002\/14651858.CD000402.pub5-BIB0040|cit40","unstructured":"France J Personal communication"},{"key":"10.1002\/14651858.CD000402.pub5-BIB0041|cit41","unstructured":"MacLennan AH Personal communication"},{"key":"10.1002\/14651858.CD000402.pub5-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"112","DOI":"10.3109\/13697139809085526","article-title":"A systematic review of the skeletal effects of estrogen therapy in postmenopausal women. II. An assessment of treatment effects","volume":"1","author":"O'Connell","year":"1998","journal-title":"Climacteric"},{"issue":"10-1","key":"10.1002\/14651858.CD000402.pub5-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0039-128X(00)00119-7","article-title":"Nestorone: a progestin with a unique pharmacological profile","volume":"65","author":"Kumar","year":"2000","journal-title":"Steroids"},{"key":"10.1002\/14651858.CD000402.pub5-BIB0044|cit44","unstructured":"Sch\u00fcnemann H Bro\u017cek J Guyatt G Oxman A editor(s) The GRADE Working Group GRADE handbook for grading quality of evidence and strength of recommendations. Updated October 2013 Available at guidelinedevelopment.org\/handbook"},{"key":"10.1002\/14651858.CD000402.pub5-BIB0045|cit45","unstructured":"GRADEpro GDT McMaster University (developed by Evidence Prime) 2023"},{"issue":"1","key":"10.1002\/14651858.CD000402.pub5-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/j.1479-828X.1995.tb01841.x","article-title":"Continuous combined piperazine oestrone sulphate and medroxyprogesterone acetate hormone replacement therapy - a study of bleeding pattern, endometrial response, serum lipid and bone density changes","volume":"35","author":"Nand","year":"1995","journal-title":"Australian & New Zealand Journal of Obstetrics & Gynaecology"},{"key":"10.1002\/14651858.CD000402.pub5-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.288.3.321","article-title":"Risks and benefits of estrogen plus progestin in healthy postmenopausal women","volume":"288","author":"Writing group for the Women's Health Initiative Investigators","year":"2002","journal-title":"Journal of the American Medical Association"},{"issue":"5 Pt 1","key":"10.1002\/14651858.CD000402.pub5-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1097\/01.AOG.0000158120.47542.18","article-title":"Menopausal symptoms and treatment-related effects of estrogen and progestin in the Women's Health Initiative","volume":"105","author":"Barnabei","year":"2005","journal-title":"Obstetrics and Gynecology"},{"key":"10.1002\/14651858.CD000402.pub5-BIB0049|cit49","doi-asserted-by":"crossref","unstructured":"Anderson GL Judd HL Kaunitz AM Barad DH Beresford SA Pettinger M Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial Journal of the American Medical Association 2003 290 13 1739 48","DOI":"10.1001\/jama.290.13.1739"},{"issue":"6","key":"10.1002\/14651858.CD000402.pub5-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/S0015-0282(01)01791-5","article-title":"Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate","volume":"75","author":"Utian","year":"2001","journal-title":"Fertility and Sterility"},{"issue":"6","key":"10.1002\/14651858.CD000402.pub5-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/S0015-0282(01)01792-7","article-title":"Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on endometrial bleeding","volume":"75","author":"Archer","year":"2001","journal-title":"Fertility and Sterility"},{"issue":"3S","key":"10.1002\/14651858.CD000402.pub5-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/S0015-0282(01)02170-7","article-title":"Endometrial safety with lower doses of conjugated equine estrogens (CEE) and medroxyprogesterone acetate (MPA)","volume":"76","author":"Pickar","year":"2001","journal-title":"Fertility and Sterility"},{"issue":"3","key":"10.1002\/14651858.CD000402.pub5-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1097\/01.GME.0000117062.54779.BD","article-title":"Body mass index does not influence response to treatment, nor does body weight change with lower doses of conjugated estrogens and medroxyprogesterone acetate in early postmenopausal women","volume":"11","author":"Utian","year":"2004","journal-title":"Menopause"},{"issue":"5","key":"10.1002\/14651858.CD000402.pub5-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/S0015-0282(03)01167-1","article-title":"Endometrial effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate: two-year substudy results","volume":"80","author":"Pickar","year":"2003","journal-title":"Fertility and Sterility"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD000402.pub5-BIB0055|cit55","first-page":"239","article-title":"Improved amenorrhoea, favourable vasomotor and lipid effects, and endometrial safety with lower doses of conjugated estrogens (CE) and medroxyprogesterone acetate (MPA)","volume":"14","author":"Archer","year":"2000","journal-title":"Gynecological Endocrinology"},{"issue":"1","key":"10.1002\/14651858.CD000402.pub5-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/AOG.0000000000002645","article-title":"A 17\u03b2-estradiol-progesterone oral capsule for vasomotor symptoms in postmenopausal women: a randomized controlled trial","volume":"132","author":"Lobo","year":"2018","journal-title":"Obstetrics and Gynecology"},{"issue":"4","key":"10.1002\/14651858.CD000402.pub5-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1097\/GME.0000000000001480","article-title":"Endometrial safety and bleeding profile of a 17beta-estradiol\/progesterone oral softgel capsule (TX-001HR)","volume":"27","author":"Mirkin","year":"2020","journal-title":"Menopause"},{"issue":"5","key":"10.1002\/14651858.CD000402.pub5-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/S0002-9378(13)90437-3","article-title":"Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens (Premarin) with medroxyprogesterone acetate or conjugated estrogens alone","volume":"170","author":"Woodruff","year":"1994","journal-title":"American Journal of Obstetrics and Gynecology"},{"issue":"6","key":"10.1002\/14651858.CD000402.pub5-BIB0059|cit59","first-page":"899","article-title":"Hormone replacement therapy: effect of progestin dose and time since menopause on endometrial bleeding","volume":"96","author":"Archer","year":"2000","journal-title":"Obstetrics and Gynecology"},{"issue":"5","key":"10.1002\/14651858.CD000402.pub5-BIB0060|cit60","first-page":"686","article-title":"Bleeding patterns in postmenopausal women taking continuous combined or sequential regimens of conjugated estrogens with medroxyprogesterone acetate","volume":"83","author":"Archer","year":"1994","journal-title":"Obstetrics and Gynecology"},{"key":"10.1002\/14651858.CD000402.pub5-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/S0002-9378(97)70037-1","article-title":"Is bleeding a predictor of endometrial hyperplasia in postmenopausal women receiving hormone replacement therapy","volume":"177","author":"Pickar","year":"1997","journal-title":"American Journal of Obstetrics and Gynecology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD000402.pub5-BIB0062|cit62","first-page":"120","article-title":"Effects of progestin dose and time since menopause on endometrial bleeding with continuous combine hormone replacement therapy","volume":"70","author":"Archer","year":"2000","journal-title":"International Journal of Obstetrics and Gynecology"},{"key":"10.1002\/14651858.CD000402.pub5-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/0002-9378(92)91653-R","article-title":"Low-dosage micronized 17B-estradiol prevents bone loss in postmenopausal women","volume":"166","author":"Ettinger","year":"1992","journal-title":"American Journal of Obstetrics and Gynecology"},{"issue":"5","key":"10.1002\/14651858.CD000402.pub5-BIB0064|cit64","first-page":"787","article-title":"Assessment of less than monthly progestin therapy in postmenopausal women given estrogen replacement","volume":"84","author":"Williams","year":"1994","journal-title":"Obstetrics and Gynecology"},{"issue":"5","key":"10.1002\/14651858.CD000402.pub5-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/j.ajog.2006.03.045","article-title":"Effects of tibolone and continuous combined conjugated equine estrogen\/medroxyprogesterone acetate on the endometrium and vaginal bleeding: results of the OPAL study","volume":"195","author":"Langer","year":"2006","journal-title":"American Journal of Obstetrics and Gynecology"},{"issue":"6","key":"10.1002\/14651858.CD000402.pub5-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1093\/eurheartj\/ehi695","article-title":"The effect of tibolone and continuous combined conjugated equine oestrogens plus medroxyprogesterone acetate on progression of carotid intima-media thickness: the Osteoporosis Prevention and Arterial effects of tiboLone (OPAL) study","volume":"27","author":"Bots","year":"2006","journal-title":"European Heart Journal"},{"issue":"6","key":"10.1002\/14651858.CD000402.pub5-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/S0197-2456(03)00096-5","article-title":"The Osteoporosis Prevention and Arterial effects of tiboLone (OPAL) study: design and baseline characteristics","volume":"24","author":"Bots","year":"2003","journal-title":"Controlled Clinical Trials"},{"issue":"6","key":"10.1002\/14651858.CD000402.pub5-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/S0015-0282(16)58690-7","article-title":"Comparison of two continuous combined estrogen progestogen regimens in postmenopausal women: a randomised trial","volume":"66","author":"AinMelk","year":"1996","journal-title":"Fertility and Sterility"},{"key":"10.1002\/14651858.CD000402.pub5-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1080\/cmt.5.1.26.35","article-title":"Endometrial safety and bleeding patterns during a 2 year study of 1 or 2 mg of 17B-estradiol combined with sequential 5-20mg dydrogesterone","volume":"5","author":"Ferenczy","year":"2002","journal-title":"Climacteric"},{"key":"10.1002\/14651858.CD000402.pub5-BIB0070|cit70","first-page":"398","article-title":"A prospective 1-year study of estrogen and progestin in postmenopausal women: effects on the endometrium","volume":"74","author":"Gelfand","year":"1989","journal-title":"Obstetrics and Gynecology"},{"issue":"12","key":"10.1002\/14651858.CD000402.pub5-BIB0071|cit71","first-page":"911","article-title":"Nylestriol replacement therapy in postmenopausal women. A three-year prospective study","volume":"106","author":"Cheng","year":"1993","journal-title":"Chinese Medical Journal"},{"issue":"5","key":"10.1002\/14651858.CD000402.pub5-BIB0072|cit72","first-page":"267","article-title":"Comparative study on two different dosages of conjugated equine estrogen continuously combined with medroxyprogesterone in prevention of postmenopausal osteoporosis","volume":"37","author":"Wu","year":"2002","journal-title":"Chinese Journal of Obstetrics & Gynecology"},{"issue":"4","key":"10.1002\/14651858.CD000402.pub5-BIB0073|cit73","first-page":"584","article-title":"A comparison of two different dosages of conjugated equine estrogen in continuous combined hormone replacement therapy with progestin","volume":"116","author":"Xing","year":"2003","journal-title":"Chinese Medical Journal"},{"issue":"2","key":"10.1002\/14651858.CD000402.pub5-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1097\/00042192-200310020-00010","article-title":"Comparison of the difference in histopathology and cell cycle kinetics among the postmenopausal endometrium treated with different progestins in sequential-combined hormone replacement therapy","volume":"10","author":"Chang","year":"2003","journal-title":"Menopause"},{"key":"10.1002\/14651858.CD000402.pub5-BIB0075|cit75","first-page":"678","article-title":"Bleeding pattern and endometrial changes during continuous combined hormone replacement therapy","volume":"91","author":"Nand","year":"1998","journal-title":"Obstetrics and Gynecology"},{"key":"10.1002\/14651858.CD000402.pub5-BIB0076|cit76","doi-asserted-by":"crossref","unstructured":"Webster M Combination continuous therapy - what is the optimal MPA dose? Effect on bleeding profiles and endometrial histology Proceedings of the 8th International Congress on the Menopause, 1996 Nov 3-7 Sydney, Australia 1996 27","DOI":"10.1016\/S0378-5122(97)80918-8"},{"issue":"1","key":"10.1002\/14651858.CD000402.pub5-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1080\/13697130310001651445","article-title":"Endometrial safety and tolerability of triphasic sequential hormone replacement estradiol valerate\/medroxyprogesterone acetate therapy regimen","volume":"7","author":"Rees","year":"2004","journal-title":"Climacteric"},{"issue":"8","key":"10.1002\/14651858.CD000402.pub5-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1001\/jama.290.8.1042","article-title":"Ultra-low-dose micronized 17beta-estradiol and bone density and bone metabolism in older women: a randomized controlled trial","volume":"290","author":"Prestwood","year":"2003","journal-title":"Journal of the American Medical Association"},{"issue":"7","key":"10.1002\/14651858.CD000402.pub5-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1001\/jama.1996.03540170041030","article-title":"The comparative effect on bone density, endometrium and lipids of continuous hormones as replacement therapy (CHART study). A randomised controlled trial","volume":"276","author":"Speroff","year":"1996","journal-title":"Journal of the American Medical Association"},{"issue":"2","key":"10.1002\/14651858.CD000402.pub5-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1067\/mob.2003.91","article-title":"A randomised, double-blind, placebo-controlled, multicenter study that assessed the endometrial effects of norethindrone acetate plus ethinyl estradiol versus ethinyl estradiol alone","volume":"188","author":"Portman","year":"2003","journal-title":"American Journal of Obstetrics and Gynecology"},{"key":"10.1002\/14651858.CD000402.pub5-BIB0081|cit81","unstructured":"Portman DJ Shumel BS Symons JP Hormone replacement therapy (HRT) with 1 mg norethindrone acetate (NA) \/ 5 mcg ethinyl estradiol (EE) (FemHRT) provides greater protection against breakthrough bleeding versus 0.625 mg combined equine estrogens (CEE) \/ 2.5 mg medroxyprogesterone (MPA) (Prempro) 3rd World Congress on Controversies in Obstetrics, Gynecology & Infertility 2002 82"},{"issue":"3","key":"10.1002\/14651858.CD000402.pub5-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/j.1471-0528.2000.tb13230.x","article-title":"Piperazine oestrone sulphate and interrupted norethisterone: effects on the postmenopausal endometrium","volume":"107","author":"Byrjalsen","year":"2000","journal-title":"British Journal of Obstetrics and Gynaecology"},{"key":"10.1002\/14651858.CD000402.pub5-BIB0083|cit83","first-page":"286","article-title":"Efficacy and safety of constant estrogen, pulsed progestin regimen in hormone replacement therapy","volume":"44","author":"Sulak","year":"1999","journal-title":"International Journal of Fertility"},{"issue":"Suppl","key":"10.1002\/14651858.CD000402.pub5-BIB0084|cit84","first-page":"S18","article-title":"One-year efficacy and safety of Prefect, a pulsed progestogen, constant estrogen hormone replacement therapy regimen","volume":"86","author":"Rozenberg","year":"1999","journal-title":"European Journal of Obstetrics, Gynecology, and Reproductive Biology"},{"key":"10.1002\/14651858.CD000402.pub5-BIB0085|cit85","doi-asserted-by":"crossref","unstructured":"Ylikorkala O Lim P Caubel P Effects on serum lipid profiles of continuous 17beta-estradiol, intermittent norgestimate regimens versus continuous combined 17beta-estradiol\/norethisterone acetate hormone replacement therapy Clinical Therapeutics 2000 22 5 622 36","DOI":"10.1016\/S0149-2918(00)80049-1"},{"key":"10.1002\/14651858.CD000402.pub5-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1034\/j.1600-0412.2002.810712.x","article-title":"Intermittent progestin administration as part of hormone replacement therapy: long-term comparison between estradiol 1 mg combined with intermittent norgestimate and estradiol 2 mg combined with constant norethisterone acetate","volume":"81","author":"Ylikorkala","year":"2002","journal-title":"Acta Obstetricia et Gynecologica Scandinavica"},{"key":"10.1002\/14651858.CD000402.pub5-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0378-5122(96)01098-5","article-title":"HRT and exercise: effects on bone density, muscle strength and lipid metabolism. A placebo controlled 2-year prospective trial on two estrogen-progestin regimens in healthy postmenopausal women","volume":"26","author":"Heikkinen","year":"1997","journal-title":"Maturitas"},{"issue":"167","key":"10.1002\/14651858.CD000402.pub5-BIB0088|cit88","first-page":"P76.33","article-title":"Comparison of bleeding patterns and endometrial histology between a three monthly and monthly cycle HRT (abstract)","volume":"76","author":"Heikkinen","year":"1997","journal-title":"Acta Obstetricia et Gynecologica Scandinavica Supplement"},{"issue":"10","key":"10.1002\/14651858.CD000402.pub5-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1056\/NEJM199603073341018","article-title":"Adverse endometrial effects of long-cycle estrogen and progestogen replacement therapy (letter)","volume":"334","author":"Cerin","year":"1996","journal-title":"New England of Journal of Medicine"},{"key":"10.1002\/14651858.CD000402.pub5-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0378-5122(99)00033-X","article-title":"Adverse endometrial effects during long cycle hormone replacement therapy","volume":"32","author":"Bjarnason","year":"1999","journal-title":"Maturitas"},{"key":"10.1002\/14651858.CD000402.pub5-BIB0091|cit91","doi-asserted-by":"crossref","unstructured":"Cerin A Hjarnason K Heldaas K Thomsen HK Boeller B Adverse endometrial effects during long cycle hormone replacement therapy Proceedings of the 8th International Congress on the Menopause, 1996, Nov 3-7 Sydney, Australia 1996 48","DOI":"10.1016\/S0378-5122(97)80981-4"},{"issue":"6","key":"10.1002\/14651858.CD000402.pub5-BIB0092|cit92","first-page":"963","article-title":"Intrauterine release of levonorgestrel - a new way of adding progestogen in hormone replacement therapy","volume":"79","author":"Andersson","year":"1992","journal-title":"Obstetrics and Gynecology"},{"issue":"1","key":"10.1002\/14651858.CD000402.pub5-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0378-5122(03)00163-4","article-title":"Continuous intrauterine compared with cyclic oral progestin administration in perimenopausal HRT","volume":"46","author":"Boon","year":"2003","journal-title":"Maturitas"},{"key":"10.1002\/14651858.CD000402.pub5-BIB0094|cit94","doi-asserted-by":"crossref","unstructured":"Boon J Scholten P Heintz AP Euser R Oldenhave A One year results of continuous intrauterine compared to cyclic oral progestin administration in combined HRT 200 perimenopausal women 8th International Congress on the Menopause, Sydney, Australia, 3-7 November 1996 94","DOI":"10.1016\/S0378-5122(97)81125-5"},{"issue":"2","key":"10.1002\/14651858.CD000402.pub5-BIB0095|cit95","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1111\/j.1471-0528.2002.01167.x","article-title":"Intrauterine 10 microg and 20 microg levonorgestrel systems in postmenopausal women receiving oral oestrogen replacement therapy: clinical, endometrial and metabolic response","volume":"109","author":"Raudaskoski","year":"2002","journal-title":"British Journal of Obstetrics and Gynaecology"},{"issue":"11","key":"10.1002\/14651858.CD000402.pub5-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1097\/01.ogx.0000361365.06151.91","article-title":"Endometrium protection and acceptability of nasally administered continuously combined hormone therapy: A multicentre, multinational, double-blind trial in postmenopausal women evaluating 3 regimens of 17beta-estradiol and norethisterone when compared with an orally administered17b-estradiol norethisterone regimen","volume":"64","author":"Rozenberg","year":"2009","journal-title":"Obstetrical & Gynecological Survey"},{"issue":"6","key":"10.1002\/14651858.CD000402.pub5-BIB0097|cit97","first-page":"519","article-title":"Vaginal micronized progesterone in continuous hormone replacement therapy: A prospective randomized study","volume":"54","author":"Ferrero","year":"2002","journal-title":"Minerva Ginecologica"},{"key":"10.1002\/14651858.CD000402.pub5-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.maturitas.2021.09.002","article-title":"Use of oral estradiol plus vaginal progesterone in healthy postmenopausal women","volume":"154","author":"Sriprasert","year":"2021","journal-title":"Maturitas"},{"issue":"5","key":"10.1002\/14651858.CD000402.pub5-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1001\/jama.1996.03530290040035","article-title":"Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen\/Progestin Interventions (PEPI) trial","volume":"275","author":"Writing Group for the PEPI trial","year":"1996","journal-title":"Journal of the American Medical Association"},{"key":"10.1002\/14651858.CD000402.pub5-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"20S","DOI":"10.1016\/0197-2456(94)00111-F","article-title":"Recruitment of postmenopausal women in the PEPI Trial","volume":"16","author":"Johnson","year":"1995","journal-title":"Controlled Clinical Trials"},{"key":"10.1002\/14651858.CD000402.pub5-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"36S","DOI":"10.1016\/0197-2456(95)96882-C","article-title":"Physical and laboratory measurements in the PEPI Trial","volume":"16","author":"Wood","year":"1995","journal-title":"Controlled Clinical Trials"},{"issue":"6","key":"10.1002\/14651858.CD000402.pub5-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1089\/15246090050118161","article-title":"Postmenopausal hormone use following a 3-year randomised clinical trial","volume":"9","author":"Barrett-Connor","year":"2000","journal-title":"Journal of Women's Health & Gender-Based Medicine"},{"key":"10.1002\/14651858.CD000402.pub5-BIB0103|cit103","first-page":"853","article-title":"Bleeding patterns of the hormone replacement therapies in postmenopausal estrogen and progestin interventions trial","volume":"100","author":"Lindenfield","year":"2002","journal-title":"Obstetrics and Gynecology"},{"key":"10.1002\/14651858.CD000402.pub5-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"1S","DOI":"10.1016\/0197-2456(94)00119-N","article-title":"The postmenopausal estrogen\/progestin interventions (PEPI) trial. Overview","volume":"16","author":"Bush","year":"1995","journal-title":"Controlled Clinical Trials"},{"key":"10.1002\/14651858.CD000402.pub5-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"3S","DOI":"10.1016\/0197-2456(94)00033-Y","article-title":"Rationale, design, and conduct of the PEPI Trial","volume":"16","author":"Espeland","year":"1995","journal-title":"Controlled Clinical Trials"},{"key":"10.1002\/14651858.CD000402.pub5-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"54S","DOI":"10.1016\/0197-2456(94)00113-H","article-title":"Baseline characteristics of the PEPI participants","volume":"16","author":"Miller","year":"1995","journal-title":"Controlled Clinical Trials"},{"issue":"1","key":"10.1002\/14651858.CD000402.pub5-BIB0107|cit107","first-page":"95","article-title":"A 12-month comparative study of raloxifene, estrogen, and placebo on the postmenopausal endometrium","volume":"95","author":"Goldstein","year":"2000","journal-title":"Obstetrics and Gynecology"},{"issue":"10","key":"10.1002\/14651858.CD000402.pub5-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1111\/j.1471-0528.1988.tb06511.x","article-title":"Comparison of four continuously administered progestogen plus oestradiol combinations for climacteric complaints","volume":"95","author":"Sporrong","year":"1988","journal-title":"British Journal of Obstetrics and Gynaecology"},{"issue":"3","key":"10.1002\/14651858.CD000402.pub5-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/0378-5122(89)90212-0","article-title":"A novel statistical approach to analysis of bleeding patterns during continuous hormone replacement therapy","volume":"11","author":"Sporrong","year":"1989","journal-title":"Maturitas"},{"issue":"1","key":"10.1002\/14651858.CD000402.pub5-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1080\/13697130310001651535","article-title":"Safety and efficacy of drospirinone used in a continuous combination with 17beta-estradiol for prevention of postmenopausal osteoporosis","volume":"7","author":"Warming","year":"2004","journal-title":"Climacteric"},{"issue":"4","key":"10.1002\/14651858.CD000402.pub5-BIB0111|cit111","first-page":"498","article-title":"A randomized comparison of continuous combined transdermal delivery of estradiol-norethindrone acetate and estradiol alone for menopause. CombiPatch Study Group","volume":"94","author":"Archer","year":"1999","journal-title":"Obstetrics and Gynecology"},{"issue":"3","key":"10.1002\/14651858.CD000402.pub5-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"338","DOI":"10.3109\/13697137.2012.717994","article-title":"Effects of bazedoxifene\/conjugated estrogens on endometrial safety and bone in postmenopausal women","volume":"16","author":"Mirkin","year":"2013","journal-title":"Climacteric"},{"issue":"12","key":"10.1002\/14651858.CD000402.pub5-BIB0113|cit113","first-page":"1355","article-title":"Safety and tolerability of bazedoxifene\/conjugated estrogens in postmenopausal women: Findings from a 1-year, randomized, placebo-and active-controlled, phase 3 trial","volume":"18","author":"Archer","year":"2011","journal-title":"Menopause"},{"issue":"2","key":"10.1002\/14651858.CD000402.pub5-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/00042192-200203000-00009","article-title":"Low dose transdermal estradiol\/norethisterone acetate treatment over 2 years does not cause endometrial proliferation in postmenopausal women","volume":"9","author":"Brynhildsen","year":"2002","journal-title":"Menopause"},{"issue":"9350","key":"10.1002\/14651858.CD000402.pub5-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1016\/S0140-6736(02)12001-0","article-title":"Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomised placebo controlled trial","volume":"360","author":"Cherry","year":"2002","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD000402.pub5-BIB0116|cit116","unstructured":"Gilmour K Effect of oestrogen replacement therapy on bleeding patterns and endometrial histology in postmenopausal women 30th British Congress of Obstetrics and Gynaecology 2004 119"},{"issue":"3","key":"10.1002\/14651858.CD000402.pub5-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1097\/01.AOG.0000137833.43248.79","article-title":"Effects of ultralow-dose transdermal estradiol on bone mineral density: A randomized clinical trial","volume":"104","author":"Ettinger","year":"2004","journal-title":"Obstetrics and Gynecology"},{"issue":"4","key":"10.1002\/14651858.CD000402.pub5-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1097\/01.AOG.0000157116.23249.52","article-title":"Uterine and vaginal effects of unopposed ultralow-dose transdermal estradiol","volume":"105","author":"Johnson","year":"2005","journal-title":"Obstetrics and Gynecology"},{"issue":"4","key":"10.1002\/14651858.CD000402.pub5-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"490","DOI":"10.3109\/13697137.2013.783797","article-title":"One-year randomized study of the endometrial safety and bleeding pattern of 0.25 mg drospirenone\/0.5 mg 17beta-estradiol in postmenopausal women","volume":"16","author":"Genazzani","year":"2013","journal-title":"Climacteric"},{"issue":"2","key":"10.1002\/14651858.CD000402.pub5-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1080\/09513590500168472","article-title":"A comparative 2-year study of the effects of sequential regimens of 1 mg 17beta-estradiol and trimegestone with a regimen containing estradiol valerate and norethisterone on the bleeding profile and endometrial safety in postmenopausal women","volume":"21","author":"Koninckx","year":"2005","journal-title":"Gynecological Endocrinology"},{"issue":"2","key":"10.1002\/14651858.CD000402.pub5-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1080\/09513590500128815","article-title":"A study of the control of climacteric symptoms in postmenopausal women following sequential regimens of 1mg 17 B-estradiol and trimegestone compared with a regimen containing 1mg estradiol valerate and norethisterone over a 2 year period","volume":"21","author":"Pornel","year":"2005","journal-title":"Gynecological Endocrinology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD000402.pub5-BIB0122|cit122","first-page":"144","article-title":"A comparative 2-year study of two sequential regimens of 1mg estradiol and trimegestone with 1mg estradiol and norethisterone upon profiles of endometrial bleeding and safety in postmenopausal women","volume":"5","author":"Koninckx","year":"2002","journal-title":"Climacteric"},{"issue":"6","key":"10.1002\/14651858.CD000402.pub5-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1093\/humrep\/16.6.1244","article-title":"A prospective randomised controlled study comparing two doses of gestodene in cyclic combined HRT preparations on endometrial physiology","volume":"16","author":"Okon","year":"2001","journal-title":"Human Reproduction"},{"issue":"3","key":"10.1002\/14651858.CD000402.pub5-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/00042192-200205000-00008","article-title":"Safety and efficacy of a continuous once-a-week 17beta-estradiol\/levonorgestrel transdermal system and its effects on vasomotor symptoms and endometrial safety in postmenopausal women: the results of two multicenter, double-blind, randomized, controlled trials","volume":"9","author":"Shulman","year":"2002","journal-title":"Menopause"},{"issue":"6","key":"10.1002\/14651858.CD000402.pub5-BIB0125|cit125","first-page":"538","article-title":"Continuous combined hormone replacement therapy with oral estradiol and promegestone: Results of a one-year trial on 3 regimens with fixed combination","volume":"12","author":"Gosset","year":"1999","journal-title":"Reproduction Humaine et Hormones"},{"issue":"2","key":"10.1002\/14651858.CD000402.pub5-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1097\/00042192-199704020-00004","article-title":"Minimal endometrial proliferation over a two-year period in postmenopausal women taking 0.3mg of unopposed esterified estrogens","volume":"4","author":"Notelovitz","year":"1997","journal-title":"Menopause"},{"issue":"3","key":"10.1002\/14651858.CD000402.pub5-BIB0127|cit127","first-page":"130","article-title":"Low-dose unopposed estrogens: preliminary findings on the frequency and duration of vaginal bleeding in postmenopausal women receiving esterified estrogens over a two-year period","volume":"4","author":"Trabal","year":"1997","journal-title":"Menopause"},{"key":"10.1002\/14651858.CD000402.pub5-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1001\/archinte.1997.00440430091011","article-title":"Low-dose esterified estrogen therapy. Effects on bone, plasma estradiol concentrations, endometrium and lipid levels","volume":"157","author":"Genant","year":"1997","journal-title":"Archives of Internal Medicine"},{"key":"10.1002\/14651858.CD000402.pub5-BIB0129|cit129","doi-asserted-by":"crossref","unstructured":"Lucas J Rebar R Speroff L Trabal J Silfen S A two-year study with low dose, continuous, unopposed esterified estrogens: prevention of postmenopausal bone loss with minimal endometrial effects Proceedings of the 8th International Congress on the Menopause, 1996, Nov 3-7 Sydney, Australia 1996 212","DOI":"10.1016\/S0378-5122(97)81499-5"},{"key":"10.1002\/14651858.CD000402.pub5-BIB0130|cit130","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1080\/13697130600953661","article-title":"Endometrial safety, overall safety and tolerability of transdermal continuous combined hormone replacement therapy over 96 weeks: a randomized open-label study","volume":"5","author":"Samsioe","year":"2006","journal-title":"Climacteric"},{"issue":"2","key":"10.1002\/14651858.CD000402.pub5-BIB0131|cit131","first-page":"196","article-title":"Long-term transdermal estradiol therapy: effects on endometrial histology and bleeding patterns","volume":"79","author":"Clisham","year":"1992","journal-title":"Obstetrics and Gynecology"},{"issue":"2","key":"10.1002\/14651858.CD000402.pub5-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.maturitas.2007.01.001","article-title":"One-year endometrial safety evaluation of a continuous combined transdermal matrix patch delivering low-dose estradiol-norethisterone acetate in postmenopausal women","volume":"57","author":"Samsioe","year":"2007","journal-title":"Maturitas"},{"key":"10.1002\/14651858.CD000402.pub5-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/0002-9378(90)90402-S","article-title":"A study of combined continuous ethinyl estradiol and norethindrone acetate for postmenopausal hormone replacement","volume":"162","author":"Williams","year":"1990","journal-title":"American Journal of Obstetrics and Gynecology"},{"issue":"3 Pt 1","key":"10.1002\/14651858.CD000402.pub5-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S0002-9378(99)70251-6","article-title":"Progestational effects of combinations of gestodene on the postmenopausal endometrium during hormone replacement therapy","volume":"180","author":"Byrjalsen","year":"1999","journal-title":"American Journal of Obstetrics and Gynecology"},{"issue":"Suppl","key":"10.1002\/14651858.CD000402.pub5-BIB0135|cit135","first-page":"19","article-title":"Progestational effects of combinations of gestodene on the postmenopausal endometrium during hormone replacement therapy","volume":"76","author":"Byrjalsen","year":"1997","journal-title":"Acta Obstetrica et Gynecologica Scandinavica"},{"issue":"6","key":"10.1002\/14651858.CD000402.pub5-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1097\/01.gme.0000184425.73567.12","article-title":"Oral hormone therapy with 17beta-estradiol and 17beta-estradiol in combination with norethindrone acetate in the prevention of bone loss in early postmenopausal women: dose-dependent effects","volume":"12","author":"Greenwald","year":"2005","journal-title":"Menopause"},{"issue":"1","key":"10.1002\/14651858.CD000402.pub5-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3109\/09513599709152317","article-title":"Placental protein 14 (PP14) does not predict endometrial status under hormone replacement therapy","volume":"11","author":"Haenggi","year":"1997","journal-title":"Gynecological Endocrinology"},{"issue":"2","key":"10.1002\/14651858.CD000402.pub5-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0378-5122(01)00260-2","article-title":"Comparative endometrial histology in postmenopausal women with sequential hormone replacement therapy of estradiol and, either chlormadinone acetate or micronized progesterone","volume":"41","author":"Jondet","year":"2002","journal-title":"Maturitas"},{"key":"10.1002\/14651858.CD000402.pub5-BIB0139|cit139","doi-asserted-by":"crossref","unstructured":"Luotola H Pyorala T Bjorn M Kaariainen J Puolakka J Long-term clinical performance of two different HRT regimens: oral combined estrogen progestin and transdermal estrogen with sequential progestin 8th International Congress on the Menopause, Sydney, Australia, 3-7 November 1996 76","DOI":"10.1016\/S0378-5122(97)81070-5"},{"issue":"3","key":"10.1002\/14651858.CD000402.pub5-BIB0140|cit140","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1258\/175404507781605596","article-title":"Efficacy and tolerability of continuous combined hormone replacement therapy in early postmenopausal women","volume":"13","author":"Mattsson","year":"2007","journal-title":"Menopause International"},{"issue":"3","key":"10.1002\/14651858.CD000402.pub5-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1080\/09513590500168464","article-title":"Bleeding profile and endometrial safety of continuous combined regimens 1 mg 17beta-estradiol\/trimegestone versus 1 or 2 mg 17beta-estradiol\/norethisterone acetate in postmenopausal women","volume":"21","author":"Bouchard","year":"2005","journal-title":"Gynecological Endocrinology"},{"issue":"2","key":"10.1002\/14651858.CD000402.pub5-BIB0142|cit142","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1080\/09513590500128971","article-title":"Efficacy on climacteric symptoms of a continuous combined regimen of 1 mg 17beta-estradiol and trimegestone versus two regimens combining 1 or 2 mg 17beta-estradiol and norethisterone acetate","volume":"21","author":"Gambacciani","year":"2005","journal-title":"Gynecological Endocrinology"},{"key":"10.1002\/14651858.CD000402.pub5-BIB0143|cit143","unstructured":"Bouchard P Addo S Spielmann D; The Trimegestone 301 Study Group A comparison of the effects of continuous combined regimens of 1mg 17B-estradiol and trimegestone with continuous combined estradiol and norethisterone acetate upon the bleeding profile and safety in postmenopausal women for up to 2 years Climacteric 2002 145"},{"key":"10.1002\/14651858.CD000402.pub5-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1001\/archinte.1991.00400100060010","article-title":"The effects of estrone (OGEN) on spinal bone density of postmenopausal women","volume":"151","author":"Harris","year":"1991","journal-title":"Archives of Internal Medicine"},{"issue":"3","key":"10.1002\/14651858.CD000402.pub5-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1067\/mob.2000.104767","article-title":"Optimizing continuous-combined hormone replacement therapy for postmenopausal women: a comparison of six different treatment regimens","volume":"182","author":"Heikkinen","year":"2000","journal-title":"American Journal of Obstetrics and Gynecology"},{"issue":"11","key":"10.1002\/14651858.CD000402.pub5-BIB0146|cit146","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1007\/s001980070031","article-title":"Long-term continuous combined hormone replacement therapy in the prevention of postmenopausal bone loss: a comparison of high- and low-dose estrogen-progestin regimens","volume":"11","author":"Heikkinen","year":"2000","journal-title":"Osteoporosis International"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD000402.pub5-BIB0147|cit147","first-page":"98","article-title":"Long-term endometrial safety of continuous combined HRT. Results from a 7-year randomised study","volume":"83","author":"Heikkinen","year":"2003","journal-title":"International Journal of Obstetrics & Gynecology"},{"key":"10.1002\/14651858.CD000402.pub5-BIB0148|cit148","doi-asserted-by":"crossref","unstructured":"Heikkinen J Vaheri R Timonen U A 10-year follow-up of postmenopausal women on long-term continuous combined hormone replacement therapy: update of safety and quality-of-life findings Journal of the British Menopause Society 2006 12 3 115 25 [erratum in Journal of the British Menopause Society 2006;12(4):174]","DOI":"10.1258\/136218006778234093"},{"issue":"3","key":"10.1002\/14651858.CD000402.pub5-BIB0149|cit149","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1258\/1362180043654647","article-title":"Long-term safety and tolerability of continuous-combined hormone therapy in postmenopausal women: results from a seven-year randomised comparison of low and standard doses","volume":"10","author":"Heikkinen","year":"2004","journal-title":"Journal of the British Menopause Society"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD000402.pub5-BIB0150|cit150","first-page":"210","article-title":"Long-term data on endometrial safety and bleeding control with a continuous combined HRT regimen","volume":"5","author":"de Weijer","year":"2002","journal-title":"Climacteric"},{"issue":"3","key":"10.1002\/14651858.CD000402.pub5-BIB0151|cit151","first-page":"207","article-title":"Evaluation of low-dose estrogen and progestin therapy in postmenopausal women","volume":"38","author":"Luciano","year":"1993","journal-title":"Journal of Reproductive Medicine"},{"issue":"1","key":"10.1002\/14651858.CD000402.pub5-BIB0152|cit152","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/0378-5122(95)00949-3","article-title":"17 beta-estradiol and norethisterone acetate in low doses as continuous combined hormone replacement therapy","volume":"23","author":"Stadberg","year":"1996","journal-title":"Maturitas"},{"issue":"4","key":"10.1002\/14651858.CD000402.pub5-BIB0153|cit153","first-page":"133","article-title":"Transdermal administration of continuous combined oestradiolnorethindrone acetate versus oestradiol only in post-menopausal women","volume":"29","author":"Tejerizo Lopez","year":"2002","journal-title":"Clinica e Investigacion en Ginecologia y Obstetricia"},{"issue":"5","key":"10.1002\/14651858.CD000402.pub5-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1007\/s00404-005-0099-6","article-title":"Effects of two different regimens of continuous hormone replacement therapy on endometrial histopathology and postmenopausal uterine bleeding","volume":"273","author":"Yildirim","year":"2006","journal-title":"Archives of Gynecology and Obstetrics"},{"issue":"6","key":"10.1002\/14651858.CD000402.pub5-BIB0155|cit155","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1097\/01.gme.0000177318.24005.b1","article-title":"Long-term safety of drospirinone-estradiol for hormone therapy: a randomised, double-blind, multicenter trial","volume":"12","author":"Archer","year":"2005","journal-title":"Menopause"},{"issue":"4","key":"10.1002\/14651858.CD000402.pub5-BIB0156|cit156","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1080\/cmt.4.4.343.354","article-title":"Acceptability and patterns of endometrial bleeding in estradiol-based HRT regimens: a comparative study of cyclical sequential combinations of trimegestone or norethisterone acetate","volume":"4","author":"Al-Azzawi","year":"2001","journal-title":"Climacteric"},{"key":"10.1002\/14651858.CD000402.pub5-BIB0157|cit157","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1093\/humupd\/dmab026","article-title":"Hormone therapy in the postmenopausal years: considering benefits and risks in clinical practice","volume":"27","author":"Genazzani","year":"2021","journal-title":"Human Reproduction Update"},{"key":"10.1002\/14651858.CD000402.pub5-BIB0158|cit158","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1056\/NEJM197606032942304","article-title":"Estrogens and endometrial cancer in a retirement community","volume":"294","author":"Mack","year":"1976","journal-title":"New England Journal of Medicine"},{"issue":"7","key":"10.1002\/14651858.CD000402.pub5-BIB0159|cit159","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1001\/jama.288.7.872","article-title":"Postmenopausal hormone replacement therapy","volume":"288","author":"Nelson","year":"2002","journal-title":"Journal of the American Medical Association"},{"key":"10.1002\/14651858.CD000402.pub5-BIB0160|cit160","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.maturitas.2016.05.013","article-title":"Hormone replacement therapy and the risk of endometrial cancer: A systematic review","volume":"91","author":"Sjogren","year":"2016","journal-title":"Maturitas"},{"key":"10.1002\/14651858.CD000402.pub5-BIB0161|cit161","first-page":"1727","article-title":"Effects of transdermal versus oral hormone replacement therapy in postmenopause: a systematic review","volume":"307","author":"Miku\u0161","year":"2023","journal-title":"Archives of Gynecology and Obstetrics"},{"key":"10.1002\/14651858.CD000402.pub5-BIB0162|cit162","unstructured":"National Institute for Health and Care Excellence (NICE) Endometrial cancer: Menopause (update) Available at https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK610154"},{"issue":"4","key":"10.1002\/14651858.CD000402.pub5-BIB0163|cit163","first-page":"523","article-title":"Sequential estrogen and progestogen therapy: assessment of progestational effects on the postmenopausal endometrium","volume":"79","author":"Byrjalsen","year":"1992","journal-title":"Obstetrics and Gynecology"},{"issue":"1","key":"10.1002\/14651858.CD000402.pub5-BIB0164|cit164","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0015-0282(98)00407-5","article-title":"Two-year prospective, randomized trial comparing an innovative twice-a-week progestin regimen with a continuous combined regimen as postmenopausal hormone therapy","volume":"71","author":"Cano","year":"1999","journal-title":"Fertility and Sterility"},{"issue":"8","key":"10.1002\/14651858.CD000402.pub5-BIB0165|cit165","first-page":"556","article-title":"Circulating hormone levels in menopausal women receiving different hormone replacement therapy regimens. A comparison","volume":"40","author":"Castelo Branco","year":"1995","journal-title":"Journal of Reproductive Medicine"},{"issue":"2","key":"10.1002\/14651858.CD000402.pub5-BIB0166|cit166","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3109\/13697130009167612","article-title":"Comparison of the efficacy and endometrial safety of two estradiol valerate\/dienogest combinations and Kliogest for continuous combined hormone replacement therapy in postmenopausal women","volume":"3","author":"Graser","year":"2000","journal-title":"Climacteric"},{"issue":"5","key":"10.1002\/14651858.CD000402.pub5-BIB0167|cit167","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1080\/gye.15.5.349.358","article-title":"A 1-year comparison of the efficacy and clinical tolerance in postmenopausal women of two hormone replacement therapies containing estradiol in combination with either norgestrel or trimegestone","volume":"15","author":"Meuwissen","year":"2001","journal-title":"Gynecological Endocrinology"},{"key":"10.1002\/14651858.CD000402.pub5-BIB0168|cit168","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/0378-5122(93)90129-6","article-title":"A two-year double-blind controlled study of the clinical effect of combined and sequential postmenopausal replacement therapy and steroid metabolism during treatment","volume":"16","author":"Obel","year":"1993","journal-title":"Maturitas"},{"issue":"2","key":"10.1002\/14651858.CD000402.pub5-BIB0169|cit169","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3109\/13697139909025573","article-title":"Bleeding patterns and endometrial histology during administration of low-dose estradiol sequentially combined with dydrogesterone","volume":"2","author":"de Weijer","year":"1999","journal-title":"Climacteric"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T08:18:18Z","timestamp":1785917898000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD000402.pub5"}},"subtitle":[],"editor":[{"name":"Cochrane Central Editorial Service","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,10,23]]},"references-count":169,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd000402.pub5","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,23]]}}}